ClinicalTrials.gg
RecruitingNCT05667610DIAMETERUpdated May 1, 2025

Immune-supportive Diet and Gut Permeability in Allergic Children

An interventional study of Immune-supportive diet and Standard care in Peanut Allergy and Nut Allergy, sponsored by Onze Lieve Vrouwe Gasthuis. Recruiting at 1 site in Netherlands. Open to participants aged 3 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-01.

Sponsored by Onze Lieve Vrouwe Gasthuis · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Sep 2022; still recruiting 4 years 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
3 Years to 17 Years
Sex
All
01

Study summary

Peanut and nut allergy can be life threatening. Some patients have very low threshold levels (i.e. the amounts of peanut and nuts to which the patients react), others react to higher doses. The reasons for these differences in threshold are not well understood. Patients with peanut and nut allergy often suffer from other allergic diseases (atopic dermatitis, hay fever and asthma). A disturbed gut microbiota composition and an increased gut permeability may explain the development of allergic disease. We hypothesize that increased gut permeability is related to low threshold levels to peanuts or nuts. In addition, as it is known that nutrition can influence our gut permeability, we also hypothesize that a healthful immune-supportive diet restores gut permeability and alleviates symptoms.

Therefore, the purpose of the study is to study in peanut and nut allergic children:

  1. the relationship between gut permeability and threshold levels to peanut or nuts;
  2. the effect of an immune-supportive diet on gut permeability, gut microbiome composition, coexisting allergic symptoms and quality of life
Read the detailed description

The incidence of allergic asthma, atopic dermatitis and food allergy started to grow to epidemic proportions after the 1960s. Peanut and nut allergy are common food allergies. Peanut allergy affects 1.4 to 3.0% of the children. Peanut and nut allergy are often lifelong and may be severe. Peanut allergy is the leading cause of (fatal) food anaphylaxis. Once peanut and nut allergy have developed, there is currently no cure other than adhering to an avoidance diet and carrying and using intramuscular epinephrine or oral antihistamines in the case of accidental ingestion. Oral immunotherapy with peanut or nuts is only applied in research setting, however, it has several drawbacks and is still in its infancy.

Inter- and intra-individual differences in threshold in peanut allergy:

Threshold levels for peanut and nuts, the lowest amount of peanut or nuts causing a reaction, may largely vary between allergic children, for which there is no clear explanation. Thresholds can be determined during oral food challenge tests with peanut or nuts in the hospital. An international multi-center study found that 5% of the children react to a low threshold of 1.7 mg of peanut protein during the food challenge in the hospital, 7.4 mg of cashew nut protein and 0.29 mg of hazelnut protein during a food challenge in the hospital. These are only traces, while 50% react to 67 mg of peanut protein. This is around 1⁄3 of a peanut, thus also a small amount. These threshold levels demonstrate how careful patients have to be in their dietary behavior. Patients with a low threshold are very sensitive to peanut or nuts and are at greater risk to react to traces of allergenic protein which can be intentionally or unintentionally present in prepacked or unpacked food. Studies have shown that the lower the threshold, the greater the impact on the health-related quality of life of the child and their parents. It is poorly understood how these differences in sensitivity (threshold levels) between individuals can be explained. Sensitization to peanut or nuts, as demonstrated by levels specific immunoglobulin E (IgE) for peanut by blood testing or the size of the skin prick test with peanut or nuts cannot explain the difference in threshold level, because they have a low predictive value for the threshold. Infection diseases illness, exercise and sleep deprivation significantly reduce the threshold level in allergic adults. However, these co-factors are not relevant in all patients, specifically not in children, and cannot explain the large differences in threshold levels observed.

Peanut and nut allergy coincides with other atopic disease:

Peanut and nut allergic children frequently suffer from other food allergies, such as milk and egg, and other coexisting atopic (allergic) diseases such as atopic dermatitis, allergic rhinitis (hay fever) and allergic asthma, leading to a substantial allergic burden in children with peanut and nut allergy. Because of the burden of these allergic conditions, the quality of life of children with food allergy is decreased, however underestimated. and even lower compared to chronic diseases, e.g. lower than children with diabetes. All these coexisting allergic diseases are based on immunologic and chronic inflammatory processes. Asthma is a systemic inflammatory disorder with a close link between the upper and the lower airways. The majority of patients with asthma have concomitant rhinosinusitis. The respiratory system is also under the influence by co-morbid conditions related to the gastrointestinal tract (food sensitization, bowel inflammation), the skin (eczema, barrier dysfunction) as well as the nervous system (neuroimmunologic network, cognitive dysfunction).

Defective mucosal barrier function (leaky gut) or increased gut permeability as possible explanation for high prevalence of allergic disease and differences in threshold to peanut or nuts:

The steep increase of allergic diseases is attributed to several lifestyle changes due to urbanization and modernization, caesarean section, use of antibiotics, a westernized pro-inflammatory diet and obesity. Firstly, according to the generally accepted hypotheses, i.e. the hygiene hypothesis and the biodiversity hypothesis, all these changes lead to microbial dysbiosis and loss of microbial diversity in the gut, which are major reasons for inflammation, inappropriate immune responses and disease development, because there is a continuous crosstalk between the intestinal microbiome and our immune system through immunomodulatory signals. Allergic diseases, such as food allergy, asthma and atopic dermatitis are all characterized by a dysbiosis and reduced diversity of the microbiome.

Secondly, one of the most recent additional explanations for the increased prevalence of allergic disease is a defective epithelial (=mucosal) barrier in the skin, gut and lungs (the "extended epithelial barrier hypothesis"). Impaired mucosal barrier function, or "leaky gut" , which results in increased gut permeability, is caused by epithelial-damaging substances linked to industrialization, urbanization and modern life, such as household and dishwashing cleaning agents and the use of (ultra) processed foods through, amongst others, emulsifiers.

An intact mucosal barrier is crucial for the maintenance of tissue homeostasis as this protects against allergens. An increased gut permeability can result in an enhanced uptake of allergens where they may activate the immune system leading to severe chronic inflammation. Thus, it is well possible that an impaired mucosal barrier function may contribute to these observed differences in threshold to peanut and nuts.

Mucosal barrier dysfunction has been demonstrated in asthma, chronic rhinosinusitis, atopic dermatitis, and Eosinophilic Esophagitis (EoE) and a number of studies in food allergy. Both the Lactulose/Mannitol ratio in urine (L/M ratio) as well as the Raffinose/Mannitol ratio in urine (R/M ratio) are commonly used Sugar Absorption Tests (SAT) for the analysis of small intestinal permeability. In the Netherlands the R/M ratio has been implemented as sugar absorption test (SAT) and is provided by Good Manufacturing Practice (GMP) certified pharmacists. If the mucosal integrity is impaired the urinary excretion of Raffinose will increase (see methods for more details). In children, for example, increased gut permeability in milk- and egg allergic children was found as compared to 7 controls. Similar results were found by Andre et al in children and adults with sensitization to foods, 0,6 - 70 years. In a study in which the relationship between allergic symptoms and mucosal permeability was studied, a significant correlation between small intestine permeability and the severity of allergic symptoms at referral was shown.

The influence of nutrition on gut permeability:

Nutrition is one of the important external factors contributing to the maintenance of an intact mucosal barrier function of the gut. In contrast, unhealthy nutrition or nutrition containing barrier-damaging agents contributes to the disruption of the mucosal barrier through the following processes:

  1. Direct effects of foods and nutrients on the maintenance or disruption of the mucosal integrity in the gut.

    Vitamin A plays a critical role in the differentiation of cells towards mucosal barrier function. Zinc and iron have an essential role in the maintenance of intestinal epithelial tight junction barrier via the regulation of claudin-3 and occluding expression. Short chain fatty acids produced through the microbial fermentation of dietary fiber, maintain mucosal integrity by processes including mucus production, tissue repair and up- regulation of the expression of tight junction proteins.

    In a small study in adult patients with eosinophilic esophagitis, it was shown that the intake of sunflower oil and/or stir fry oil, as well as the total amount of added fat, was negatively (i.e., unfavorably) related to in vitro values of permeability, while the consumption of buttermilk/yoghurt drink with Lactobacillus rhamnosus, dairy and vitamin A were favorably related to mucosal permeability of the esophagus.

    In contrast nutrition may also may have deleterious effects on the mucosal barrier function. Emulsifiers in highly processed foods are surfactants that behave like detergents, and even trace amounts of these agents markedly increase bacterial translocation in mouse models. Advanced Glycation End products (AGE) formation and additives commonly used by the food industry in highly processed foods play a role.

    Thus, our diet may be one of the key factors in the maintenance or impairment of our epithelial barrier function, and may as such contribute to the prevention and treatment of chronic immune disorders.

  2. Our diet is an important source for the composition of our microbiome and regulation of the mucosal barrier function.

    Healthy dietary constituents feed our gut microbiota by providing substrates for a large variety of intestinal microbial species, leading to a diverse and anti-inflammatory microbiome. Dietary fiber, vegetables, legumes, grains, nuts, fish, plant-based foods, fermented dairy (e.g. buttermilk and yoghurt), omega-3 polyunsaturated fatty acids n-3 and polyphenols have anti-inflammatory capacity through modulation of our gut microbiota composition with a protective effect on our mucosal barrier function by regulation of tight junction barriers. Higher intake of animal foods, saturated fat, processed foods, alcohol and sugar induce pro-inflammatory processes by the reduction of the total abundance and reduction of specific species of bacteria in our gut and subsequent negative impact on our mucosal barrier function. Plant-based proteins and n-3 polyunsaturated fatty acids induce the opposite effect alongside increased abundance of anti-inflammatory species.

  3. Nutrition provides nutrients which are essential for the functioning of the innate and adaptive immune system, which in turn regulate the mucosal barrier function. T cells, type 2 innate lymphoid cells (IL2) and interleukine 13 (IL13)play major roles. According to very strict criteria several nutrients are recognized by European Food Safety Authority (EFSA) for their immunomodulatory properties. These are copper, folate, iron, selenium, vitamin A, B6, B12, C, D and zinc.
  4. Our diet can induce either pro-inflammatory or anti-inflammatory effects in the gut and our body. Diet is established among the most important influences on health in modern societies. Poor diet is among the leading causes of chronic disease. The composition of our diet may importantly enhance or reduce inflammation and may therefore influence inflammatory disease such as asthma and atopic dermatitis, This cannot be contributed to single foods, instead, the total dietary pattern is important. A Western diet which is characterized by a high consumption of meat, highly processed foods, ready-to-use foods and meals, refined grains, sugar, omega-6 fatty acids and saturated fatty acids, and a low consumption of dietary fiber, omega 3 fatty acids, anti-oxidants, fruits, vegetables and plant-based foods. Such a diet induces a pro-inflammatory state of our immune system and increased intestinal permeability.

In contrast, dietary patterns such as a traditional Mediterranean diet, with high contents of monounsaturated (MUFA), ω-3 polyunsaturated fatty acid, home-made meals, fruits, vegetables, legumes, and grains, has shown anti-inflammatory effects when compared with typical North American and Northern European dietary patterns. With regards to allergic disease specifically, the use of organic dairy and unprocessed milk is associated with lower prevalence of allergic diseases, as was shown in the KOALA birth cohort study and studies on children on farms.

Taken together, for peanut and nut allergy there is yet no cure and threshold levels to peanut or nuts differ widely for reasons unknown. Peanut and nut allergy often present in patients with coexisting atopic diseases such as atopic dermatitis and atopic asthma, which are based on inflammatory processes. An impaired mucosal barrier may contribute to the observed differences in thresholds to peanut and nuts. Nutrition can either positively or negatively influence our immune function, gut microbiota composition and gut permeability, and therefore may influence threshold levels to peanut and nuts, as well as severity of coexistent symptoms such as atopic dermatitis and asthma.

Thus, a study on dietary intervention as proposed in this protocol will yield lacking knowledge on the effect of a healthful diet on gut permeability and clinical symptoms in allergic disease.

The study will be performed in children as peanut and nut allergy are often lifelong, may be severe, cannot yet be cured and has a significant impact on quality of life which is underestimated by parents. The risk of inadvertent allergic reactions specifically holds for children with a low threshold to peanut. With a higher threshold level fewer products need to be avoided which will improve quality of life. In addition, comorbidity in allergic disease such as eczema is most prominent in children. Therefore, children will most benefit from our study results if we can show immune-supportive diet improves gut barrier function and alleviates allergic symptoms.

02

Conditions studied

  • Peanut Allergy
  • Nut Allergy

Keywords

  • Gut permeability
  • Immune-supportive diet
  • Thresholds
03

In context

Peanut Hypersensitivity

166 studies on the registry are indexed under Peanut Hypersensitivity; 27 are open to participants now.

This study's planned enrollment of 132 is above the median of 50 across 127 interventional studies indexed under Peanut Hypersensitivity.

Browse Peanut Hypersensitivity studies →

Lead sponsor

Onze Lieve Vrouwe Gasthuis is the lead sponsor of 23 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children of 3 to 17 years of age with a positive open or double-blind placebo-controlled peanut or nut challenge \< 12 months to inclusion OR an obvious and objective IgE-mediated allergic reaction following the consumption of isolated peanut or nut within 1 hours, confirmed by sensitisation to peanut or nut \< 24 months to inclusion;
  • Children who are potty trained or house trained;
  • Presence of IgE to peanut ≥0.35 kilo units per liter (kU/l) or skin prick test > 3 mm to peanut or nut, \< 12 months prior to challenge.

Exclusion criteria

Exclusion Criteria:

  • Only mild symptoms in the oral cavity to peanut or nut due to pollen food syndrome;
  • A negative peanut or nut challenge;
  • Children who are not potty trained (house trained);
  • Gastro-intestinal diseases (e.g. Morbus Crohn, coeliac disease, Colitis Ulcerosa), lactose intolerance
  • severe cow's milk allergy -because of possible traces of cow's milk in lactose in the SAT), syndromes, infectious/immunology diseases other than atopy, or diabetes;
  • Laxative treatment, such as lactulose;
  • Not able to read or write Dutch.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    Intervention group (immune-supportive diet)

    * Immune-supportive diet (for 4 months) on top of peanut and/or nut free diet. Foods are allocated into 3 food groups: 1. Recommended in ample amounts: with an acknowledged beneficial role in immune health (first choice foods); 2. Recommended in limited amounts: with an acknowledged beneficial role in immune health when used in limited amounts (second choice foods). 3. Not recommended: with an acknowledged unfavourable role in immune health (third choice foods) * Self-assessed feasibility and adherence to the Immune-supportive diet (intervention group only) a by Likert scale after 2,5 and 4 months of dietary intervention; * Dietary adherence will be determined by the researchers after 4 months by calculating the number of first and second choice foods based on the food diaries after dietary intervention.

    Other: Immune-supportive diet

  • Active comparator
    Control group

    - Peanut and/or nut free diet only

    Other: Standard care

Interventions

  • OtherImmune-supportive diet

    The intervention includes a immune-supportive diet over a period of 4 months

  • OtherStandard care

    Standard care: Peanut or nut free diet

06

What researchers measure

Primary outcomes

  1. Changes in small intestine permeability between baseline and after 4 months of dietary intervention as expressed by the Raffinose/Mannitol ratio in urine

    We will measure the ratio of Raffinose/Mannitol in urine at baseline and after 4 months of dietary intervention

    Time frame: 4 months

Secondary outcomes

  1. Relationship between gut permeability and the severity of atopic dermatitis

    Gut permeability is measured by R/M ratio. Severity of atopic dermatitis is measured by SCORAD

    Time frame: At baseline

  2. Relationship between gut permeability and patient reported outcomes of asthma and allergic rhinitis

    Gut permeability is measured by R/M ratio. Severity of Asthma and allergic rhinitis symptoms are measured by the Onderzoek astma en hooikoorts bij kinderen questionnaire (Caratkids)

    Time frame: At baseline

  3. Relationship between gut permeability and patient reported outcomes of gastrointestinal symptoms

    Gut permeability is measured by R/M ratio. Gastrointestinal symptoms are measured by the Birmingham irritable bowel syndrome (IBS) questionnaire in Dutch

    Time frame: At baseline

  4. Relationship between gut permeability and treshold levels to peanut or nuts

    The relationship between gut permeability (R/M ratio) and threshold level to peanut or nuts established during the oral food challenge (cumulative mg peanut or nut protein);

    Time frame: At baseline

  5. Differences in gut microbiota composition

    Microbiota compostion will be measured by by gene sequencing technology (16S methods)

    Time frame: At baseline and after 4 months

  6. Differences in severity of atopic dermatitis

    Differences in severity of atopic dermatitis measured (Scorad-score)

    Time frame: At baseline and after 4 months

  7. Differences in atopic dermatitis (POEM)

    Differences in atopic dermatitis (POEM)

    Time frame: At baseline and after 4 months

  8. Differences in asthma

    Differences in asthma (Caratkids)

    Time frame: At baseline and after 4 months

  9. Differences in gastro-intestinal symptoms

    Differences in gastro-intestinal symptoms (Birmingham IBS questionnaire, Dutch version)

    Time frame: At baseline and after 4 months

  10. Differences in use of medications

    Use of medication will be registered by a Medication Registration Form (MRF).

    Time frame: At baseline and after 4 months

  11. Differences in upper respiratory tract infections (URTIs)

    Differences in upper respiratory tract infections (URTIs) by questionnaire (numbe fo days, doctor's visits, antibiotics, days off from school or work

    Time frame: At baseline and after 4 months

  12. Differences in food allergy quality of Life

    Food allergy quality of life will be measured by disease-specific and age-related quality of life questionnaires (FAQLQ-ChildForm, FAQLQ-ParentForm and FAQLQ-TeenagerForm)

    Time frame: At baseline and after 4 months

  13. Self-assessed dietary adherence and feasibility of the Immune-supportive diet (intervention group only)

    Self-assessed dietary adherence and feasibility of the Immune-supportive diet (intervention group only) will be measured by Likert scales

    Time frame: 2,5 and 4 months

  14. Relationship between gut permeability and nutritional intake

    Gut permeability is measured by R/M ratio Dietary intervention (in grams of food) will be assessed by three online 24-hour food recalls

    Time frame: At baseline and after 4 months

  15. Calcultated dietary adherence

    Calculated dietary adherence by the researcher by the number of first and second choice foods in 3-days food diaries after 4 months of dietary intervention

    Time frame: At baseline and after 4 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — As the database contains patient (coded) information the database can be shared under request

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05667610
Lead sponsor
Onze Lieve Vrouwe Gasthuis
Collaborators
Ekhaga foundation, Rijnstate Hospital, Noordwest Ziekenhuisgroep, Erasmus Medical Center, Wageningen University, Amsterdam UMC, Utrecht Institute for Pharmaceutical Sciences, Diakonessenhuis, Utrecht, Deventer Ziekenhuis, Harvard University
Responsible party
Sponsor
First posted
Dec 28, 2022
Start date
Sep 8, 2022
Primary completion
Jun 30, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
May 1, 2025

Study contacts

Berber Vlieg-Boerstra
Contact
b.vlieg-boerstra@olvg.nl
+31620965612
Chantal den Elzen, MSc
Contact
c.denelzen@olvg.nl
+31627538421

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion